开放和封闭三联吸入器治疗未控制哮喘患者。

IF 1.8 Q3 RESPIRATORY SYSTEM

Advances in respiratory medicine Pub Date : 2023-07-04 DOI:10.3390/arm91040023

Serafeim-Chrysovalantis Kotoulas, Ioanna Tsiouprou, Kalliopi Domvri, Polyxeni Ntontsi, Athanasia Pataka, Konstantinos Porpodis

{"title":"开放和封闭三联吸入器治疗未控制哮喘患者。","authors":"Serafeim-Chrysovalantis Kotoulas, Ioanna Tsiouprou, Kalliopi Domvri, Polyxeni Ntontsi, Athanasia Pataka, Konstantinos Porpodis","doi":"10.3390/arm91040023","DOIUrl":null,"url":null,"abstract":"Long-acting muscarinic antagonists (LAMAs) are a class of inhalers that has recently been included as add-on therapy in the GINA guidelines, either in a single inhaler device with inhaled corticosteroids plus long-acting β2-agonists (ICS + LABA) (closed triple inhaler therapy) or in a separate one (open triple inhaler therapy). This review summarizes the existing evidence on the addition of LAMAs in patients with persistently uncontrolled asthma despite ICS + LABA treatment based on clinical efficacy in the reduction of asthma symptoms and exacerbations, the improvement in lung function, and its safety profile.","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366885/pdf/","citationCount":"1","resultStr":"{\"title\":\"Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma.\",\"authors\":\"Serafeim-Chrysovalantis Kotoulas, Ioanna Tsiouprou, Kalliopi Domvri, Polyxeni Ntontsi, Athanasia Pataka, Konstantinos Porpodis\",\"doi\":\"10.3390/arm91040023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Long-acting muscarinic antagonists (LAMAs) are a class of inhalers that has recently been included as add-on therapy in the GINA guidelines, either in a single inhaler device with inhaled corticosteroids plus long-acting β2-agonists (ICS + LABA) (closed triple inhaler therapy) or in a separate one (open triple inhaler therapy). This review summarizes the existing evidence on the addition of LAMAs in patients with persistently uncontrolled asthma despite ICS + LABA treatment based on clinical efficacy in the reduction of asthma symptoms and exacerbations, the improvement in lung function, and its safety profile.\",\"PeriodicalId\":7391,\"journal\":{\"name\":\"Advances in respiratory medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2023-07-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366885/pdf/\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in respiratory medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/arm91040023\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in respiratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/arm91040023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 1

摘要

长效毒蕈碱拮抗剂(LAMAs)是一类最近被纳入GINA指南的附加治疗的吸入器，无论是在吸入皮质类固醇加长效β2激动剂(ICS + LABA)的单一吸入器装置中(闭式三联吸入器治疗)还是在单独的吸入器中(开放式三联吸入器治疗)。本文综述了在ICS + LABA治疗后持续不受控制的哮喘患者中添加LAMAs的现有证据，包括在减轻哮喘症状和加重、改善肺功能和安全性方面的临床疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma.

查看原文本刊更多论文

Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma.

Long-acting muscarinic antagonists (LAMAs) are a class of inhalers that has recently been included as add-on therapy in the GINA guidelines, either in a single inhaler device with inhaled corticosteroids plus long-acting β2-agonists (ICS + LABA) (closed triple inhaler therapy) or in a separate one (open triple inhaler therapy). This review summarizes the existing evidence on the addition of LAMAs in patients with persistently uncontrolled asthma despite ICS + LABA treatment based on clinical efficacy in the reduction of asthma symptoms and exacerbations, the improvement in lung function, and its safety profile.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Advances in respiratory medicine RESPIRATORY SYSTEM-

CiteScore

2.60

自引率

0.00%

发文量

期刊介绍： "Advances in Respiratory Medicine" is a new international title for "Pneumonologia i Alergologia Polska", edited bimonthly and addressed to respiratory professionals. The Journal contains peer-reviewed original research papers, short communications, case-reports, recommendations of the Polish Respiratory Society concerning the diagnosis and treatment of lung diseases, editorials, postgraduate education articles, letters and book reviews in the field of pneumonology, allergology, oncology, immunology and infectious diseases. "Advances in Respiratory Medicine" is an open access, official journal of Polish Society of Lung Diseases, Polish Society of Allergology and National Research Institute of Tuberculosis and Lung Diseases.